YS BIOPHARMA CO LTD (YS)
KYG9845F1090 - Common Stock
1.32 -0.01 (-0.75%)
After market: 1.31 -0.01 (-0.76%)
YS Biopharma to Participate in the Virtual Benchmark Healthcare House Call Conference on May 23, 2023
/PRNewswire/ -- YS Biopharma Co., Ltd. (NASDAQ: YS) ("YS Biopharma" or the "Company"), a global biopharmaceutical company dedicated to discovering, developing,...
YS Biopharma's PIKA Rabies Vaccine Receives Phase 3 Clinical Trial Approval in Pakistan
/PRNewswire/ -- YS Biopharma Co., Ltd. (NASDAQ: YS) ("YS Biopharma" or the "Company"), a global biopharmaceutical company dedicated to discovering, developing,...
YS, SMIH LOSS ALERT: ROSEN, A GLOBALLY RECOGNIZED LAW FIRM, Encourages YS Biopharma Co., Ltd. f/k/a Summit Healthcare Acquisition Corp. Investors to Inquire About Securities Class Action Investigation - YS, SMIH
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.
YS, SMIH INVESTOR NOTICE: ROSEN, SKILLED INVESTOR COUNSEL, Encourages YS Biopharma Co., Ltd. f/k/a Summit Healthcare Acquisition Corp. Investors to Inquire About Securities Class Action Investigation - YS, SMIH
/PRNewswire/ -- WHY: Rosen Law Firm, a global investor rights law firm, announces an investigation of potential securities claims on behalf of shareholders of...
NASDAQ: YS Investor Alert: Investigation over Possible Securities Laws Violations by YS Biopharma Co., Ltd.
San Diego, CA -- (SBWIRE) -- 05/09/2023 -- YS Biopharma Co., Ltd. is under investigation over potential securities laws violations in connection with certain financial statements.
ROSEN, LEADING INVESTOR COUNSEL, Encourages YS Biopharma Co., Ltd. f/k/a Summit Healthcare Acquisition Corp. Investors to Inquire About Securities Class Action Investigation - YS, SMIH
/PRNewswire/ -- WHY: Rosen Law Firm, a global investor rights law firm, announces an investigation of potential securities claims on behalf of shareholders of...
ROSEN, SKILLED INVESTOR COUNSEL, Encourages YS Biopharma Co., Ltd. f/k/a Summit Healthcare Acquisition Corp. Investors to Inquire About Securities Class Action Investigation - YS, SMIH
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.
YS Biopharma Announces Record Vaccine Revenues and Preliminary Financial Results for FY2023 Ended March 31, 2023
/PRNewswire/ -- YS Biopharma Co., Ltd. (NASDAQ: YS) ("YS Biopharma" or the "Company"), a global biopharmaceutical company dedicated to discovering, developing,...
YS Biopharma's PIKA Recombinant COVID-19 Vaccine Demonstrates Superior Antibody Neutralization Responses Compared to Inactivated COVID-19 Vaccine in Phase II Head-to-Head Clinical Study
The trial met its primary endpoint of superior immunogenicity of PIKA COVID-19 Vaccine vs inactivated COVID-19 vaccine, measured by GMT of neutralizing...